Ustekinumab is effective and safe and shows a high rate of clinical remission and treatment persistence in patients with ulcerative colitis.
1hon MSN
'I saw blood on my leg at kickboxing and within weeks I was going to the bathroom 25 times a day'
His condition quickly escalated - leaving him having "bloody accidents" and a slew of embarrassing bathroom stories. Louie ...
The rheumatoid arthritis therapeutics market is set for growth driven by innovative biosimilars like Cyltezo and Hyrimoz, ...
A lot of people don't realise it, but the condition of gut health determines the state of our overall health. People who ...
When Sherry received a diagnosis of endometrial cancer, her life was forever changed. Learn more about her journey.
Merck earns a 'Strong Buy' rating with robust Q2 drug sales, share buybacks, and new EMA approvals. Click here to read my ...
Investing.com -- Spyre Therapeutics (NASDAQ:SYRE) stock rose 4% Friday after Deutsche Bank analyst David Hoang initiated coverage with a Buy rating and a $43 price target, suggesting significant ...
TipRanks on MSN
Spyre Therapeutics initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Spyre Therapeutics (SYRE) with a Buy rating and $43 price target The company’s goal is to create improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback